Beta frequency synchronization in basal ganglia output during rest and walk in a hemiparkinsonian rat.
Synchronized oscillatory neuronal activity in the beta frequency range has been observed in the basal ganglia of Parkinson's disease patients and hypothesized to be antikinetic. The unilaterally lesioned rat model of Parkinson's disease allows examination of this hypothesis by direct comparison of beta activity in basal ganglia output in non-lesioned and dopamine cell lesioned hemispheres during motor activity. Bilateral substantia nigra pars reticulata (SNpr) recordings of units and local field potentials (LFP) were obtained with EMG activity from the scapularis muscle in control and unilaterally nigrostriatal lesioned rats trained to walk on a rotary treadmill. After left hemispheric lesion, rats had difficulty walking contraversive on the treadmill but could walk in the ipsiversive direction. During inattentive rest, SNpr LFP power in the 12-25 Hz range (low beta) was significantly greater in the dopamine-depleted hemisphere than in non-lesioned and control hemispheres. During walking, low beta power was reduced in all hemispheres, while 25-40 Hz (high beta) activity was selectively increased in the lesioned hemisphere. High beta power increases were reduced by l-DOPA administration. SNpr spiking was significantly more synchronized with SNpr low beta LFP oscillations during rest and high beta LFP oscillations during walking in the dopamine-depleted hemispheres compared with non-lesioned hemispheres. Data show that dopamine loss is associated with opposing changes in low and high beta range SNpr activity during rest and walk and suggest that increased synchronization of high beta activity in SNpr output from the lesioned hemisphere during walking may contribute to gait impairment in the hemiparkinsonian rat.
Avila
Irene
I
Neurophysiological Pharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Drive, Building 35 Room 1C 905, Bethesda, MD 20892-3702, USA.
Parr-Brownlie
Louise C
LC
Brazhnik
Elena
E
Castañeda
Edward
E
Bergstrom
Debra A
DA
Walters
Judith R
JR
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use; D001479:Basal Ganglia / Q000293:injuries / Q000503:physiopathology*; D001611:Beta Rhythm; D004298:Dopamine / Q000378:metabolism; D004576:Electromyography / Q000379:methods; D005071:Evoked Potentials / Q000502:physiology; D005080:Exercise Test; D007839:Functional Laterality / Q000187:drug effects; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D016627:Oxidopamine; D010300:Parkinson Disease / Q000188:drug therapy / Q000209:etiology / Q000473:pathology* / Q000503:physiopathology*; D051381:Rats; D020318:Rats, Long-Evans; D012146:Rest / Q000502:physiology*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism; D016138:Walking / Q000502:physiology*
D000978:Antiparkinson Agents; D007980:Levodopa; D016627:Oxidopamine; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine